Drug Profile
Research programme: small molecule therapeutics - Chinook Therapeutics/ HitGen
Latest Information Update: 18 Aug 2023
Price :
$50
*
At a glance
- Originator HitGen
- Developer Chinook Therapeutics; HitGen
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 11 Aug 2023 Chinook Therapeutics has been acquired by Novartis
- 28 Sep 2021 No recent reports of development identified for research development in Unspecified in USA
- 05 Oct 2020 Aduro Biotech has been merged with Chinook Therapeutics to form Chinook Therapeutics